Arranon and Etoposide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Arranon (nelarabine) and Etoposide (etoposide). Common drug interactions include bacteraemia among females and platelet count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Arranon and Etoposide. It is created by eHealthMe based on reports of 42 people who take the same drugs from the FDA, and is updated regularly.

What is Arranon?

Arranon has active ingredients of nelarabine. eHealthMe is studying from 289 Arranon users. Check the latest studies of Arranon.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

42 people who take Arranon and Etoposide together, and have interactions are studied.

Arranon and Etoposide drug interactions.

What are the common drug interactions of Arranon and Etoposide, by gender? *:

female:

Bacteraemia (presence of bacteria in the blood)
Bladder dysfunction
C-reactive protein increased
Cytokine storm (over-protective immune response that can actually be fatal)
Diffuse axonal injury (traumatic brain injury)
Functional gastrointestinal disorder (functional problem in separate organs of gastrointestinal system)
Hypertriglyceridaemia (excess of triglycerides in the blood)
Muscular weakness (muscle weakness)
Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
Neutrophil count increased (excess than normal number of neutrophil a type of blood cell)

male:

Platelet count decreased
Febrile neutropenia (fever with reduced white blood cells)
Anorectal disorder
Appendicitis perforated (perforated appendicitis is a condition in which an inflamed appendix bursts)
Bladder disorder
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Histiocytosis haematophagic
Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection)
Myelopathy (any neurologic deficit related to the spinal cord)
Hyperbilirubinaemia (excess of bilirubin in the blood)

What are the common drug interactions of Arranon and Etoposide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Restlessness (not able to rest)
Dysarthria (speech disorder)
Eyelid ptosis (falling of the upper or lower eyelid)
Headache (pain in head)
Nystagmus (a condition of involuntary eye movement)
Abnormal behaviour
Anger
Crying
Mood altered (changes in mood)
Visual impairment

10-19:

Renal failure acute (rapid kidney dysfunction)
Areflexia (absence of a reflex)
Decreased vibratory sense
Dyspnoea (difficult or laboured respiration)
Fall
Haemoglobin decreased
Hypersensitivity
Monoplegia (a paralysis of a single limb)
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Muscle atrophy (a decrease in the mass of the muscle)

20-29:

Osmotic demyelination syndrome (increased serum sodium level leads to hyponatremic encephalopathy)
Bone marrow tumour cell infiltration
Dysstasia (difficulty in standing)
Gait disturbance
Myelitis (infection or the inflammation of white matter or gray matter of spinal cord which is a part of central nervous system)
Sensory disturbance (sense disturbance)
Thrombocytopenia (decrease of platelets in blood)

30-39:

Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)

40-49:

Blood creatine phosphokinase increased
Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
Depressed level of consciousness
Febrile neutropenia (fever with reduced white blood cells)
Myalgia (muscle pain)
Renal impairment (severely reduced kidney function)
White blood cell count decreased
Aphthous stomatitis (mouth ulcer)
Aphthous ulcer (mouth ulcer)
Cardiac failure

50-59:

Myelitis (infection or the inflammation of white matter or gray matter of spinal cord which is a part of central nervous system)
Peripheral motor neuropathy (muscles in the body become progressively weaker over months to years)
Peripheral sensory neuropathy (damage to one or more of your peripheral nerves)

60+:

Memory impairment
Dysstasia (difficulty in standing)
Gait disturbance
Limb discomfort (discomfort in leg)
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
Sensory disturbance (sense disturbance)

What are the existing conditions these people have? *

Neoplasm Malignant (cancer tumour): 27 people, 64.29%
T-Cell Type Acute Leukaemia (a form of cancer of the white blood cells): 16 people, 38.10%
Allergies: 9 people, 21.43%
Infection: 8 people, 19.05%
Nausea And Vomiting: 7 people, 16.67%
Hepatic Function Abnormal: 6 people, 14.29%
Urination - Excessive Volume: 5 people, 11.90%
Precursor T-Lymphoblastic Lymphoma/leukaemia (precursor b-cell cancer): 5 people, 11.90%
Gastritis (inflammation of stomach): 4 people, 9.52%
Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 4 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Arranon and Etoposide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously